Display options
Cite
Lekpa FK, Farrenq V, Claudepierre P. Spondylarthropathies. [Spondylarthropathies]. Rev Prat. 2009;59(4):519-32
Lekpa, F. K., Farrenq, V., & Claudepierre, P. (2009). Spondylarthropathies. [Spondylarthropathies]. La Revue du praticien, 59(4), 519-32.
Lekpa, Fernando Kemta, et al. "Spondylarthropathies." [Spondylarthropathies]. La Revue du praticien vol. 59,4 (2009): 519-32.
Lekpa FK, Farrenq V, Claudepierre P. Spondylarthropathies. [Spondylarthropathies]. Rev Prat. 2009 Apr 20;59(4):519-32. French. PMID: 19462874.
Copy Download .nbib Format: NLM
Share it on

Rev Prat. 2009 Apr 20;59(4):519-32.

[Spondylarthropathies].

La Revue du praticien

[Article in French]
Fernando Kemta Lekpa, Valérie Farrenq, Pascal Claudepierre

Affiliations

  1. Service de rhumatologie, CHU Albert Chenevier-Henri Mondor, AP-HP, UFR Médecine Paris-XII, 94010 Créteil Cedex.

PMID: 19462874

Abstract

Spondylarthropathies include the ankylosing spondylitis, psoriatic arthritis, reactive arthritis, arthritis of inflammatory bowel disease (Crohn disease, ulcerative colitis), some juvenile arthritis and undifferenciated spondylarthropathies. These diseases are linked together by a basic elementary lesion, enthesitis, common clinical and radiological features (sacroiliitis, spondylitis, peripheral arthritis, extra-articular manifestations), and association with HLA B27 antigen. Prevalence of spondylarthropathies in France is estimated at 0.3%, with no difference between women and men. Therapeutic option associate physical therapy and anti-inflammatory drugs. In case of insufficient efficacy of these conventional drugs, TNFalpha antagonist therapy can be used in axial forms, after disease modifying drugs in peripheral forms.

MeSH terms

Publication Types